


SUPPLEMENTARY INFORMATION


Short-term repeat HPV testing for triaging HPV-positive women in cervical cancer screening

Table of contents


Supplementary Figure 1. Time (months) until the second HPV test. Horizontal dashed line: 3 months.....	2
Supplementary Figure 2. ESTAMPA participants by HPV type test: HC2 or Cobas.....	2
Supplementary Figure 3. Positivity of 2nd HPV test by age and type of test	3
Supplementary Table 1. Overall and age-stratified performance of repeat HPV testing for detection of CIN2+ among HPV-screened-positive women by type of test	3
Supplementary Table 2. Performance of baseline limited HPV genotyping obtained from the Cobas screening test for detection of CIN3+ among HPV-screened-positive women	4



Supplementary Figure 1. Time (months) until the second HPV test. Horizontal dashed line: 3 months



Supplementary Figure 2. ESTAMPA participants included in the analyses by HPV type test: HC2 or Cobas



Supplementary Figure 3. Positivity of 2nd HPV test among HPV-positive women by age and type of test. Overall test-specific positivity was 57.4% for HC2 and 68.2% for Cobas (Table 1). Dashed line: overall positivity regardless of type of test (61%)

Supplementary Table 1. Overall and age-stratified performance of repeat HPV testing for detection of CIN2+ among HPV-positive women by type of test

Type of HPV test	Performance for detection of CIN2+				Referral (95% CI)
	Se (95% CI)	Sp (95% CI)	PPV (95% CI)	cNPV (95% CI)	
<i>HC2 HPV repeat test</i>					
All women					
Positive	79.4	47.2	24.0	8.4	57.4
Negative	(76.0-82.4)	(45.4-49.1)	(22.1-25.9)	(7.1-9.9)	(55.7-59.0)
Women <50 years					
Positive	80.4	48.6	26.9	8.7	56.9
Negative	(76.8-83.7)	(46.5-50.7)	(24.8-29.2)	(7.2-10.4)	(55.0-58.8)
Women 50+ years					
Positive	74.3	43.4	15.2	7.5	58.7
Negative	(65.2-81.7)	(39.9-46.9)	(12.3-18.5)	(5.2-10.7)	(55.4-62.0)
<i>P-value *</i>	<i>0.199</i>	<i>0.014</i>	<i><0.001</i>	<i>0.553</i>	<i>0.363</i>
<i>Cobas HPV repeat test</i>					
All women					
Positive	86.5	36.3	25.1	8.4	68.2
Negative	(82.7-89.5)	(34.0-38.7)	(22.8-27.5)	(6.5-10.9)	(66.1-70.2)
Women <50 years					
Positive	86.5	36.8	29.6	10.1	68.7
Negative	(82.5-89.8)	(34.0-39.7)	(26.9-32.5)	(7.7-13.2)	(66.3-71.0)
Women 50+ years					
Positive	86.0	35.1	11.2	3.7	66.7
Negative	(72.7-93.4)	(30.8-39.6)	(8.3-15.1)	(1.7-7.8)	(62.5-70.7)
<i>P-value*</i>	<i>1.000</i>	<i>0.573</i>	<i><0.001</i>	<i>0.017</i>	<i>0.449</i>

*Pearson's chi-squared test to compared performance measures between women aged 50 years or older versus younger women. Se: sensitivity, Sp: specificity, PPV: positive predictive value, cNPV: complement of negative predictive value.

Supplementary Table 2. Performance of baseline limited HPV genotyping obtained from the Cobas screening test for detection of CIN3+ among HPV-positive women

	<CIN2	CIN2	CIN3	Cancer	Performance* for detection of CIN3+				Referral
	n (%)	n (%)	n (%)	n (%)	Se (95% CI)	Sp (95% CI)	PPV (95% CI)	cNPV (95% CI)	(95% CI)
Baseline HPV16 (N=1,947)									
HPV16 positive	237 (60.5)	15 (3.8)	134 (34.2)	6 (1.5)	43.1	84.8	37.1	12.3	20.0
HPV16 negative	1,325 (85.2)	45 (2.9)	177 (11.4)	8 (0.5)	(37.8-48.5)	(83.0-86.5)	(32.4-42.1)	(10.7-14.0)	(18.2-21.8)
Baseline HPV16/18 (N=1,947)									
HPV16/18 positive	342 (63.2)	24 (4.4)	166 (30.7)	9 (1.7)	53.8	78.1	33.8	10.9	27.4
HPV16/18 negative	1,220 (86.8)	36 (2.6)	145 (10.3)	5 (0.4)	(48.4-59.2)	(76.0-80.1)	(29.9-38.0)	(9.4-12.7)	(25.4-29.5)

*CIN2 cases are excluded from Sp, PPV, and cNPV estimates. Se: sensitivity, Sp: specificity, PPV: positive predictive value, cNPV: complement of negative predictive value. Row percentages are shown.